AI Access Brief Podcast
By Carl Haakon
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Carl Haakon
Category: Management
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 159
Description
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and evidence strategy.
| Episode | Date |
|---|---|
|
Access Brief 154: HCA, Leqembi, FTC & ICER
|
Oct 30, 2026 |
|
CMS Star Ratings, NICE Digital Health, EU Oncology JCAs
|
Oct 29, 2026 |
|
US Access Erosion & Pricing Signals
|
Oct 28, 2026 |
|
Leqembi SubQ, FTC Insulin, ICER Advice, HCA Warning
|
Oct 27, 2026 |
|
US Healthcare Access & Value Shifts
|
Oct 26, 2026 |
|
HTA Evidence Evolution & IRA Impact
|
Oct 25, 2026 |
|
Access Erosion Signals & New Pathways
|
Oct 24, 2026 |
|
HTA Frameworks & Pricing Pressures
|
Oct 23, 2026 |
|
HCA Warning, Leqembi SubQ, FTC Insulin, ICER Advice
|
Oct 22, 2026 |
|
HTA Evolution & Market Access
|
Oct 21, 2026 |
|
Profit Warning, Leqembi, Insulin, ICER
|
Oct 20, 2026 |
|
HCA Warning & Leqembi Shift
|
Oct 19, 2026 |
|
HCA Warning, Leqembi, FTC, ICER
|
Oct 18, 2026 |
|
US Access Erosion Signals
|
Oct 17, 2026 |
|
HTA Methodology Shifts & Alzheimer's Access
|
Oct 16, 2026 |
|
HTA Methodology Shifts & AI Integration
|
Oct 14, 2026 |
|
HCA Warning, Leqembi SC, FTC CVS, ICER Advice
|
Oct 13, 2026 |
|
FDA CAR-T Approval & NICE CGT Framework
|
Oct 12, 2026 |
|
Payer Evidence Demands
|
Oct 11, 2026 |
|
US Market Access Shifts: Profit Warnings, New Approvals, and Policy Changes
|
Oct 10, 2026 |
|
US Access Shifts: Leqembi, PBMs, and Early HEOR Strategy
|
Oct 09, 2026 |
|
HTA Framework Evolution & Digital Guidance
|
Oct 08, 2026 |
|
EMA AI Paper, NICE RWE Pilot, CMS Value Model, ISPOR Digital Framework
|
Oct 07, 2026 |
|
Gene Therapy Value & HTA Evolution
|
Oct 06, 2026 |
|
FDA RWE Guidance & CMS Star Ratings
|
Oct 05, 2026 |
|
HCA Warning, Leqembi Shift, FTC Insulin, ICER Advice
|
Oct 04, 2026 |
|
HCA Warning, Leqembi SubQ, FTC CVS, ICER Advice
|
Oct 03, 2026 |
|
RWE Guidance, Star Ratings, Digital Therapeutics, EU HTA
|
Oct 02, 2026 |
|
HTA Method Shifts & IRA Implications
|
Oct 01, 2026 |
|
HCA Warning & Leqembi Access
|
Sep 30, 2026 |
|
Access Erosion Signals & Leqembi Shift
|
Sep 29, 2026 |
|
CMS Rebate Shift & NICE Threshold
|
Sep 28, 2026 |
|
Access Erosion & Value Signals
|
Sep 27, 2026 |
|
FDA RWE Guidance & CMS Star Ratings
|
Sep 26, 2026 |
|
HTA Methodological Shifts & Pricing Pressures
|
Sep 25, 2026 |
|
HCA Warning, Leqembi SubQ, FTC CVS, ICER Advice
|
Sep 24, 2026 |
|
Profit Warnings & Scientific Advice
|
Sep 23, 2026 |
|
HCA Warning, Leqembi Shift, Insulin PBM, ICER Advice
|
Sep 20, 2026 |
|
Supportive Care RWE, Cell Therapy Budget Impact, Patient-Centric HTA
|
Sep 19, 2026 |
|
HCA Warning, Leqembi, FTC, ICER Expansion
|
Sep 18, 2026 |
|
Star Ratings, Decentralized Trials, Gene Therapy Frameworks, RWE Guidance
|
Sep 17, 2026 |
|
HTA Method Shifts & Pricing Trends
|
Sep 16, 2026 |
|
Access Erosion Signals & Value Frameworks
|
Sep 15, 2026 |
|
HTA Evolution & Access Pressures
|
Sep 14, 2026 |
|
HCA Warning, Leqembi Shift, PBM Scrutiny
|
Sep 13, 2026 |
|
Global HTA Shifts & Digital Health
|
Sep 12, 2026 |
|
HCA Warning & Leqembi Shift
|
Sep 11, 2026 |
|
CMS Gene Therapy Coverage & RWE Integration
|
Sep 10, 2026 |
|
HTA Evolution & AI Governance
|
Sep 09, 2026 |
|
Access Erosion & Value Signals
|
Sep 08, 2026 |
|
Profit Warnings & Insulin Pricing
|
Sep 07, 2026 |
|
Market Access Headlines: HCA, Leqembi, Insulin, ICER
|
Sep 06, 2026 |
|
Elections, AI, and Value Pricing
|
Sep 04, 2026 |
|
HTA in Fragile Settings
|
Sep 03, 2026 |
|
Patient Advocacy & HTA Evolution
|
Sep 02, 2026 |
|
HCA Warning, Leqembi SubQ, FTC Insulin
|
Sep 01, 2026 |
|
Leqembi SubQ, HCA Access, FTC Insulin, ICER Advice
|
Aug 31, 2026 |
|
HTA Method Shifts & RWE Expansion
|
Aug 30, 2026 |
|
Accelerated Approvals & Value Models
|
Aug 29, 2026 |
|
HCA Warning & Leqembi Approval
|
Aug 28, 2026 |
|
FDA RWD Guidance & CMS Star Ratings
|
Aug 27, 2026 |
|
US Healthcare Access & Pricing Shifts
|
Aug 25, 2026 |
|
HTA Evolution & Digital Health
|
Aug 24, 2026 |
|
FDA Accelerations, CMS Models, NICE RWE
|
Aug 23, 2026 |
|
US Access Signals & Global Shifts
|
Aug 22, 2026 |
|
Profit Warnings & Pricing Pressures
|
Aug 21, 2026 |
|
HTA Method Shifts & RWE Integration
|
Aug 20, 2026 |
|
HCA Warning, SubQ Leqembi, FTC Insulin, ICER Advice
|
Aug 19, 2026 |
|
HTA Digital Shifts & Pricing Pressures
|
Aug 18, 2026 |
|
HCA Warning, Leqembi, Insulin, ICER
|
Aug 16, 2026 |
|
Gene Therapy Access & RWE Guidance
|
Aug 15, 2026 |
|
HCA Warning, Leqembi, Insulin, ICER
|
Aug 13, 2026 |
|
Profit Warnings & Insulin Pricing
|
Aug 12, 2026 |
|
HCA Warning, Leqembi, FTC, ICER
|
Aug 11, 2026 |
|
HTA Methodology Shifts & Digital Health Integration
|
Aug 05, 2026 |
|
System Stress & Evidence Shifts
|
Aug 04, 2026 |
|
US Access Signals & HEOR Shifts
|
Aug 03, 2026 |
|
Market Access Crosscurrents
|
Aug 01, 2026 |
|
HTA Alignment & Gene Therapy Value
|
Jul 29, 2026 |
|
HCA Profit Warning & Insulin Pricing Shifts
|
Jul 28, 2026 |
|
US Market Access Shifts
|
Jul 27, 2026 |
|
Profit Warning, Approval, Settlement, Expansion
|
Jul 26, 2026 |
|
HCA Profit Warning & SubQ Leqembi
|
Jul 25, 2026 |
|
Profit Warnings & Pricing Scrutiny
|
Jul 24, 2026 |
|
US Access & Evidence Shifts
|
Jul 23, 2026 |
|
EMA RWE Pediatric Pilot & CMS Rebate Shift
|
Jul 22, 2026 |
|
Profit Warnings, Insulin Settlements, and Leqembi
|
Jul 21, 2026 |
|
HTA Evidence Evolution
|
Jul 20, 2026 |
|
HTA Methodology Shifts & Pricing Pressures
|
Jul 19, 2026 |
|
HTA Methodology Shifts & FDA Accelerated Approvals
|
Jul 18, 2026 |
|
HTA & RWE Shifts
|
Jul 17, 2026 |
|
HTA Evolution & Pricing Realities
|
Jul 16, 2026 |
|
KRAS Breakthrough & HTA Realities
|
Jul 15, 2026 |
|
HTA Pathways & Real-World Evidence
|
Jul 15, 2026 |
|
Market Access Crossroads
|
Jul 15, 2026 |
|
US Pricing Dynamics & Biomarker Therapies
|
Jul 15, 2026 |
|
US Healthcare System Strain & Innovation
|
Jul 14, 2026 |
|
Trodelvy, Orkambi, EU AI Diagnostics
|
Jul 14, 2026 |
|
AI, RWE, Thresholds & Orphan Drugs
|
Jul 14, 2026 |
|
Gulf HTA & Africa RWE
|
Jul 13, 2026 |
|
JCA Timelines & Regulatory Divergence
|
Jul 12, 2026 |
|
Global HTA Divergence
|
Jul 11, 2026 |
|
JCA Reports & Regulatory Divergence
|
Jul 10, 2026 |
|
JCA Reports & Regulatory Divergence
|
Jul 09, 2026 |
|
JCA Reports & Global HTA Shifts
|
Jul 08, 2026 |
|
HTA Method Shifts & Digital Evidence
|
Jul 07, 2026 |
|
PRAC Valproate, Middle East HTA, Canada Pricing, RWE Latin America, Asia Gene Therapy
|
Jul 06, 2026 |
|
JCA Reports & Regulatory Divergences
|
Jul 05, 2026 |
|
JCA Reports & Regulatory Divergences
|
Jul 04, 2026 |
|
Gene Therapy & RWE Challenges
|
Jul 03, 2026 |
|
HTA Thresholds & Geopolitical HTA
|
Jul 02, 2026 |
|
HTA Methodology Shifts & Pricing Pressures
|
Jun 30, 2026 |
|
CHMP Approvals, Aligned Pathway, JCA Scale-up
|
Jun 29, 2026 |
|
JCA Reports & Regulatory Divergence
|
Jun 28, 2026 |
|
RWE, Gene Therapy, IRA Evidence Challenges
|
Jun 27, 2026 |
|
HTA Realities & RWE Gaps
|
Jun 26, 2026 |
|
Divergent Pathways
|
Jun 25, 2026 |
|
Regulatory Divergence HEOR Impacts
|
Jun 25, 2026 |
|
PRAC Valproate, JCA Scale-Up, EMA Emergency Trials
|
Jun 22, 2026 |
|
Avacopan Crisis, D-VRd Reversal, Mirvetuximab Access
|
Jun 17, 2026 |
|
First JCA Report, Oral Wegovy, Camizestrant Divergence
|
Jun 17, 2026 |
|
JCA Devices Live, Camizestrant Divergence, JSC Window Open
|
Jun 17, 2026 |
|
PRAC Valproate Review, JCA Scale-Up, Emergency Trial Guidance
|
Jun 15, 2026 |
|
EU JCA Medical Devices Launch, MHRA-NICE First Guidance
|
Jun 14, 2026 |
|
MHRA-NICE Aligned Pathway and EU JCA Operationalization
|
Jun 13, 2026 |
|
First JCA Published, CHMP Patterns, Device Expansion
|
Jun 12, 2026 |
|
First JCA Report and Oral Semaglutide Approval
|
Jun 10, 2026 |
|
CHMP Pipeline Shift and Critical Medicines Act Mandates
|
Jun 09, 2026 |
|
Medical Device JCAs Launch and Novel Mechanism Approvals
|
Jun 08, 2026 |
|
NICE Diabetes Revolution, EU Device JCAs, Clinical Trial Acceleration
|
Jun 07, 2026 |
|
Orphan Dominance and Oral Semaglutide Market Shifts
|
Jun 06, 2026 |
|
DMD Access Breakthrough and CHMP Pipeline Shift
|
Jun 05, 2026 |
|
RNA Breakthroughs, Critical Medicines Act, and Evidence Judgment Era
|
Jun 04, 2026 |
|
First-in-Class HEOR Challenges and Regulatory Framework Shifts
|
Jun 03, 2026 |
|
CHMP Approvals Signal Shift, JCA Device Rollout Begins
|
Jun 02, 2026 |
|
Medical Device JCAs Launch and NICE Methodology Shifts
|
Jun 01, 2026 |
|
CHMP Rare Disease Pipeline and NICE Threshold Implementation
|
May 31, 2026 |
|
Device JCAs Launch, NICE Prioritisation, and MFN Reality Check
|
May 30, 2026 |
|
Critical Medicines Act, AI Tops HEOR Trends, NICE Advice ROI
|
May 29, 2026 |
|
EQ-5D-5L Update Reshapes Cancer Economics
|
May 28, 2026 |
|
MHRA-NICE Pathway Under Fire, Clinical Trial Targets Hit
|
May 27, 2026 |
|
CHMP Pipeline Surge, NICE Threshold Jump, JCA Device Push
|
May 27, 2026 |
|
Critical Medicines Act and NICE Technology Priorities
|
May 27, 2026 |
|
NICE Unified Prioritisation and EMA Regulatory Momentum
|
May 27, 2026 |
|
UK Alignment Acceleration and EU JCA Implementation
|
May 27, 2026 |
|
Oral GLP-1s, AI Dominance, and Digital Health Parity
|
May 27, 2026 |
|
NICE Threshold Shift, Critical Medicines Act, and MFN Reality Check
|
May 26, 2026 |
|
Critical Medicines Act Shapes EU HTA Landscape
|
May 26, 2026 |
|
CHMP Momentum, Critical Medicines Act, HTA Capacity Scaling
|
May 26, 2026 |
|
HTACG Data Transparency and NICE Prioritisation Overhaul
|
May 25, 2026 |
|
Critical Medicines Act Agreement and EMA Pipeline Momentum
|
May 24, 2026 |
|
Critical Medicines Act Agreement and JCA Operational Momentum
|
May 20, 2026 |
|
Critical Medicines Act, NICE Threshold Changes, EU JCA Capacity
|
May 20, 2026 |
|
NICE Approves Givinostat for DMD and EU Critical Medicines Act Progress
|
May 18, 2026 |
|
Critical Medicines Act Agreement and MHRA-NICE Pathway Launch
|
May 18, 2026 |
|
ISPOR Week: The Evidence Generation Timing Gap
|
May 12, 2026 |
|
MFN Agreements, Heart Failure Evidence, and JCA Timelines
|
May 11, 2026 |
|
When The News Slows: Strategy Through Quiet Cycles
|
May 11, 2026 |
|
JCA at Sixteen Months, Survodutide Phase III, and ISPOR 2026
|
May 11, 2026 |